RECEIVED
CENTRAL FAX CENTER
OCT 26 2007

AMENDMENTS TO THE CLAIMS

The following Listing of Claims shall replace any prior listing of claims. No new matter has been added.

Listing of Claims

1. (Original) A compound as shown in formula (A):



(A)

wherein,

R is methyl, ethyl, propyl, *iso*-propyl, or butyl;

W is  ;

R' is methyl, ethyl, propyl, *iso*-propyl, or butyl;

R'' is methyl, ethyl, propyl, *iso*-propyl, or butyl; and

M is a metal ion.

2. (Original) The compound of Claim 1 having the following formula:



Formula (I)

wherein R is as defined above.

3. (Original) The compound of Claim 1 having the following formula:



Formula (II)

wherein R is as defined above; and

M is lithium, sodium, potassium or calcium.

4. (Original) The compound of Claim 1 having the following formula:



Formula (III)

wherein, R, R', and R'' are as defined above; and

M is lithium, sodium, potassium or calcium.

5. (Original) The compound of Claim 1, wherein the compound is selected from the group consisting of:

Compound 1: 2,2-dimethylbutyricacid-3-hydroxy-8-[2-(4-hydroxy-6-oxo-tetrahydro pyran-2-yl)-ethyl]-7-methyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl ester;

Compound 2: the compound of formula (II), wherein R=methyl, M=K;

Compound 3: the compound of formula (III), wherein R=R'=R''=methyl, M=K.

6. (Original) A pharmaceutical composition comprising an effective amount of the compound of formula (A) and a pharmaceutically acceptable carrier.

7. (Currently Amended) The synthetic method of the compound of formula (I), wherein the method comprises the steps of:

starting from pravastatin, after the protection of the carboxylic group with formation of alkali metal salt, the 2-position of the 2-methylbutyryl group in the 8-~~posotion~~ position of the hydrogenated naphthalene is alkylated with alkyl halide;

or the method comprises the following steps:

starting from pravastatin, after the carboxylic group is converted into amide and the hydroxyl group is protected by siloxane, the 2-methylbutyryl group in the 8-~~posotion~~ position of the hydrogenated naphthalene is transformed into 2,2-dimethylbutyryl group with alkyl halide.

8. (Original) The synthetic method of the compound of formula (II), comprising the steps of:

reacting β-hydroxyl carboxylic acid, i.e., the product of the ring-opening reaction of the compound of formula (I), with a base of formula MOH, thereby forming the compound of formula (II), wherein M is lithium, sodium or potassium.

9. (Original) The synthetic method of the compound of formula (III), comprising the steps of:

in the presence of ketone or 2,2-dialkoxylpropane, converting the β, δ –dihydroxyl carboxylic acid, i.e., the product of the ring-opening reaction of the compound of formula (I), into 6-member ring ketal by acid catalysis, and

reacting the ketal with the base of formula MOH, thereby forming the compound of formula (III),

wherein M is lithium, sodium or potassium.

10. (Currently Amended) A method of manufacturing a medicament for inhibiting hydroxylmethyl glutaryl coenzyme A reductase, comprising:

preparing ~~use of~~ the compound of formula (A) as in claim 1 ~~in the manufacture of drugs for inhibiting hydroxylmethyl glutaryl coenzyme A reductase~~; and

preparing a pharmaceutical composition including the compound of formula A.